[德国霍奇金淋巴瘤研究组HD1、HD2和HD3治疗研究的中期结果] - Suppr | 超能文献

[Intermediate results of therapy studies HD1, HD2 and HD3 of the German Hodgkin Study Group].

作者信息

Diehl V, Pfreundschuh M, Hauser F E, Löffler M, Rühl U, Brücher H, Georgii A, Hiller E, Gerhartz H

出版信息

Med Klin (Munich). 1986 Jan 17;81(1):1-6.

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

[Intermediate results of therapy studies HD1, HD2 and HD3 of the German Hodgkin Study Group].[德国霍奇金淋巴瘤研究组HD1、HD2和HD3治疗研究的中期结果]

Med Klin (Munich). 1986 Jan 17;81(1):1-6.

2

The concept, evolution and preliminary results of the current Stanford clinical trials for Hodgkin's disease.

Cancer Surv. 1985;4(2):459-75.

3

[Staging of Hodgkin's disease and choice of treatment].[霍奇金淋巴瘤的分期与治疗选择]

Nihon Rinsho. 1983 Nov;41(11):2482-9.

4

Hodgkin's disease - new treatment strategies toward the cure of patients.霍奇金淋巴瘤——迈向治愈患者的新治疗策略

Cancer Treat Rev. 1999 Jun;25(3):169-76. doi: 10.1053/ctrv.1999.0114.

5

[New therapeutic strategies for Hodgkin lymphoma in cooperation of radiation oncology and medical oncology].[放射肿瘤学与医学肿瘤学合作下霍奇金淋巴瘤的新治疗策略]

Rontgenpraxis. 2003;55(3):114-24.

6

Current role and future developments of radiotherapy in early-stage favourable Hodgkin's lymphoma.放射治疗在早期预后良好型霍奇金淋巴瘤中的当前作用及未来发展

Strahlenther Onkol. 2007 Dec;183 Spec No 2:16-8. doi: 10.1007/s00066-007-2007-4.

7

Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group.霍奇金淋巴瘤横断面成像的集中放射肿瘤学审查导致德国霍奇金淋巴瘤研究组质量保证计划中所需受累野发生显著变化。

Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1121-7. doi: 10.1016/j.ijrobp.2003.08.033.

8

[Hodgkin's disease 1986].[霍奇金淋巴瘤 1986 年]

Med Clin (Barc). 1987 Feb 7;88(5):188-91.

9

[A retrospective analysis of the treatment results in Hodgkin's disease in a radiotherapy clinic].[某放疗诊所霍奇金病治疗结果的回顾性分析]

Strahlenther Onkol. 1994 Sep;170(9):516-23.

10

New therapies in Hodgkin's lymphoma.霍奇金淋巴瘤的新疗法。

Clin Adv Hematol Oncol. 2004 Feb;2(2):80, 83.

引用本文的文献

1

Chemotherapy of Hodgkin's lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine). Results of the HD1 and HD3 trials of the German Hodgkin Study Group.采用COPP（环磷酰胺、长春新碱、丙卡巴肼、泼尼松）和ABVD（阿霉素、博来霉素、长春花碱和达卡巴嗪）交替疗程治疗霍奇金淋巴瘤。德国霍奇金研究组HD1和HD3试验结果。

Med Oncol Tumor Pharmacother. 1989;6(2):155-62. doi: 10.1007/BF02985239.

2

Prognostic risk factors in advanced Hodgkin's lymphoma. Report of the German Hodgkin Study Group.晚期霍奇金淋巴瘤的预后危险因素。德国霍奇金淋巴瘤研究组报告

Blut. 1988 Jun;56(6):273-81. doi: 10.1007/BF00320290.